drugset / Trial / NCT01078376

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

NCT01078376

Phase 1 Terminated 29 enrolled Takeda
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.

Timeline

Start
2010-05
Primary completion
2013-07
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 0.66 mg/kg Oral
Subject Azilsartan medoxomil Other / unclassified 20 mg Oral
Subject Azilsartan medoxomil Other / unclassified 60 mg Oral
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral

Indications